Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 20:3:141-5.
doi: 10.1016/j.bbacli.2014.09.001. eCollection 2015 Jun.

Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients

George Boon-Bee Goh  1 , Mangesh R Pagadala  1 , Jaividhya Dasarathy  2 , Aynur Unalp-Arida  3 , Ruth Sargent  1 , Carol Hawkins  4 , Achuthan Sourianarayanane  1 , Amer Khiyami  4 , Lisa Yerian  5 , Rish K Pai  5 , Srinivasan Dasarathy  6 , Arthur J McCullough  6
Affiliations

Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients

George Boon-Bee Goh et al. BBA Clin. .

Abstract

Background: While non-alcoholic fatty liver disease (NAFLD) has been well characterised in patients with diabetes mellitus (DM), less is known about NAFLD in non-DM patients. We investigated the clinical characteristics of NAFLD patients with and without DM and accuracy of the NAFLD fibrosis score (NFS) in these two NAFLD groups.

Methods: Clinical, biochemical and histological variables were evaluated in this prospective cross-sectional study of 503 patients with biopsy proven NAFLD. Comparisons between patients with and without DM were analysed. NFS was correlated with liver histology to assess its robustness in patients with and without DM.

Results: There were 503 biopsy proven NAFLD patients with 48% of the cohort being diabetic. Relative to patients without DM, patients with DM were older (52 vs. 46 years, p < 0.001), with higher proportion of females (70% vs. 54%, p < 0.001), higher BMI (37 vs. 35, p = 0.009), higher prevalence of hypertension (73% vs. 44%, p < 0.001), higher prevalence of NASH (80.2% vs. 64.4%; p < 0.001) and advanced fibrosis (40.3% vs. 17.0%; p < 0.001). A considerable amount of patients without DM still had NASH (64%) and advanced fibrosis (17%). The clinical utility of the NFS differed between NAFLD patients with and without DM, with sensitivity to exclude advanced fibrosis being 90% of NAFLD patients with DM but only 58% of patients without DM.

Conclusion: Patients with DM have more severe NAFLD based on histology. However, NASH and advanced fibrosis also occur in a considerable proportion of NAFLD patients without DM. The lower utility of the NFS in NAFLD patients without DM emphasises the heterogeneous nature of the NAFLD phenotype.

Keywords: ACE-I, angiotensin-converting enzyme-inhibitor; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BMI, body mass index; CIs, confidence intervals; Chol, total cholesterol; DM, type 2 diabetes mellitus; Diabetic; ER, endoplasmic reticulum; FFAs, free-fatty acids; HDL, high density lipoprotein cholesterol; HOMA-IR, Homeostatic model assessment—insulin resistance; INR, international normalised ratio; LDL, low density lipoprotein cholesterol; NAFLD; NAFLD fibrosis score; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH CRN, Non-alcoholic Steatohepatitis Clinical Research Network; NASH, non-alcoholic steatohepatitis; NFS, NAFLD fibrosis score; Non-diabetic; ORs, odd ratios; SDs, standard deviations; TGs, triglycerides; VLDL, very-low-density lipoproteins; apoB-100, apolipoprotein B-100.

PubMed Disclaimer

References

    1. Marchesini G., Bugianesi E., Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–923. - PubMed
    1. Chalasani N., Younossi Z., Lavine J.E. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2023. - PubMed
    1. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011;43(8):617–649. - PubMed
    1. Younossi Z.M., Reyes M.J., Mishra A., Mehta R., Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis — a case for personalised treatment based on pathogenic targets. Aliment. Pharmacol. Ther. 2014;39(1):3–14. - PubMed
    1. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000. - PubMed

LinkOut - more resources